HYL.BR

Hyloris Pharmaceuticals SA [HYL.BR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HYL.BR Stock Summary

Top 10 Correlated Stocks

HYL.BR

In the News

HYL.BR Financial details

Company Rating
-
Market Cap
341.6M
Income
-26.53M
Revenue
5.76M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
40
Optionable
No
Shortable
Yes
Earnings
14 Mar 2024
P/E
-32.83
Forward P/E
-
PEG
-2.35
P/S
123.35
P/B
6.42
P/C
-
P/FCF
-26.2
Quick Ratio
7.61
Current Ratio
8.8
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.96
EPS next Y
-
EPS next Q
-
EPS this Y
40%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-13.4%
Revenue last 5Y
98.64%
Revenue Q/Q
42.59%
EPS Q/Q
33.33%
-
-
-
-
SMA20
-
SMA50
-20%
SMA100
-20%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-21%
ROC
-0.19%
Gross Margin
97%
Oper. Margin
-356%
Profit Margin
-365%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.6-14.1
52W High
-73.43%
52W Low
-62.8%
RSI
32
Rel Volume
0.3
Avg Volume
11.76K
Volume
3.53K
Perf Week
-13.69%
Perf Month
-15.84%
Perf Quarter
-33.81%
Perf Half Y
-36.95%
-
-
-
-
Beta
0.576
-
-
Volatility
0.17%, 0.19%
Prev Close
-5.82%
Price
3.72
Change
-7%

Something similar

Top by Market Cap
MSFT
META
GOOGL
MSF.DE
FB2A.DE
Same Sector
NVNO
IOLCP.NS
4XT.DE
7780.T
ALBPS.PA
Top Correlated Stocks
STW.ST
0NES.L
NEPA.ST
FACC.VI
AAC.ST
Similar Market Cap
CATC
HT
LRGE
SUULD.NS
MIVU.PA

Company Profile

Healthcare Biotechnology
  • Volume Average 11.76K
  • Market Capitalization 341.6M
  • Employee 40
  • CEO Mr. Stijn Van Rompay
  • Headquarters Liège,BE
  • IPO Date 2020-06-29
  • Website https://hyloris.com

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.